{
  "symbol": "REGN",
  "year": 2022,
  "period": "Q1",
  "curated_text": "Symbol: REGN. Year: 2022. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Development Risks \u2022 Drug, Intellectual Property and Market Exclusivity Risks \u2022. Context excerpt: competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates. \u2022 We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad. Regulatory and Development Risks \u2022 Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain. \u2022 Serious complications or side effects in connection with the use or development of our products or product candidates could cause our regulatory approvals to be revoked or limited or lead to delay or discontinuation of development of our product candidates or new indications for our marketed products. \u2022 We may be unable to formulate or manufacture our product candidates in a way that is suitable for clinical or commercial use, which would delay or prevent continued de",
  "competition_summary": [
    {
      "competitor": "Development Risks \u2022 Drug",
      "mentions": 1,
      "context": "competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates. \u2022 We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad. Regulatory and Development Risks \u2022 Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consumi"
    },
    {
      "competitor": "Intellectual Property and Market Exclusivity Risks \u2022",
      "mentions": 1,
      "context": "competition from products or product candidates that may be superior to, or more cost effective than, our products or product candidates. \u2022 We and our collaborators on which we rely to commercialize some of our marketed products may be unable to continue to successfully commercialize or co-commercialize our products, both in the United States and abroad. Regulatory and Development Risks \u2022 Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consumi"
    }
  ]
}